Literature DB >> 28942430

Interventions for smoking cessation in patients admitted with Acute Coronary Syndrome: a review.

Omar M Chehab1,2, Habib A Dakik1.   

Abstract

Tobacco smoking contributes to about six million deaths per year and is predicted to increase in the future. Several pharmacological interventions are used for smoking cessation. Trials using nicotine replacement therapy (NRT) in acute coronary syndrome (ACS) showed inconclusive results. Furthermore, three trials using bupropion in patients admitted with ACS failed to show improvement in smoking cessation compared with placebo. Interestingly, only one trial using varenicline was successful in achieving smoking abstinence in the acute setting. With regard to behavioural interventions, a meta-analysis found that telephone counselling was successful in both the acute and stable settings, with greater effect in the acute setting. The best results for smoking cessation were found in trials that used a combination of pharmacological and behavioural interventions. The objective of this report is to review the results of studies on interventions used for smoking cessation after an ACS. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Behavioral interventions.; Bupropion; Hospitalized; Nicotine Replacement Therapy; Smoking cessation; Varenicline

Mesh:

Substances:

Year:  2017        PMID: 28942430     DOI: 10.1136/postgradmedj-2017-135040

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  1 in total

1.  Medication-assisted quit rates in participants with smoking-related diseases in EAGLES: Post hoc analyses of a double-blind, randomized, placebo-controlled clinical trial.

Authors:  Philip Tønnesen; David Lawrence; Serena Tonstad
Journal:  Tob Induc Dis       Date:  2022-05-10       Impact factor: 5.163

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.